

1/2w

PTO/SB/21 (09-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/602,441	
	Filing Date	June 24, 2003	
	First Named Inventor	Anish Sen Majumdar, et al.	
	Art Unit	1642	
	Examiner Name	Susan Nmn Ungar	
Total Number of Pages in This Submission	6	Attorney Docket Number	086/002

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement (2 pages)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<b>Remarks</b> 1. PTO Form 1449 (3 pages) with copies of 57 references 2. Return receipt postcard	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Geron Corporation		
Signature			
Printed name	J. Michael Schiff		
Date	March 4/05	Reg. No.	40,253

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Anish Sen Majumdar, *et al.*

Art Unit: 1642

Serial No.: 10/602,441

Examiner: Susan Nmn Ungar

Filing Date: June 24, 2003

Attorney Docket: 086/002

For: CANCER VACCINES CONTAINING  
XENOGENEIC EPITOPES OF TELOMERASE  
REVERSE TRANSCRIPTASE

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Arlington, VA 22313-1450


Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

It is believed that no fee is required for submission of this Statement, which is filed before the first Office Action on the merits of the application. Nevertheless, should a fee be required for consideration of this Statement and the listed information, the Commissioner is authorized to charge such fee to Deposit Account No. 07-1139, referencing the attorney Docket Number indicated above.

Respectfully submitted,


A handwritten signature in black ink, appearing to read "J. Michael Schiff", is written over a large, hand-drawn oval. The signature is fluid and cursive.

J. Michael Schiff  
Registration No. 40,253

GERON CORPORATION  
230 Constitution Drive  
Menlo Park, CA 94025  
*Telephone: (650) 473-7715*  
*Fax: (650) 473-8654*

March 4, 2005

Form 1449 (modified)	Docket: 086/002	U.S.S.N.: 10/602,441
INFORMATION DISCLOSURE	Title: Cancer Vaccines Containing Xenogeneic Epitopes of Telomerase Reverse Transcriptase	
STATEMENT BY APPLICANT	Inventors: Anish Sen Majumdar, <i>et al.</i>	
(Use Several Sheets if Necessary)	Filing Date: June 24, 2003	Group: 1642




**U.S. PATENT DOCUMENTS**

Examiner Initial	Document No.	Filing Date	Publication Date	Class/ Subclass	Inventors	Title
	A 5,583,016	Oct 27/94	Dec 10/96	435/91.3	Villeponteau B et al	Mammalian Telomerase
	B 5,853,719	Apr 30/96	Dec 29/98	424/93.21	Nair SK et al	Methods for Treating Cancers and Pathogen Infections Using Antigen-Presenting Cells Loaded with RNA
	C 6,166,178	Nov 19/97	Dec 26/00	530/324	Cech TR et al	Telomerase Catalytic Subunit
	D 6,261,836	May 9/97	Jul 17/01	435/325	Cech TR et al	Telomerase
	E 6,274,378	Oct 27/98	Aug 14/01	435/377	Steinman RM et al	Methods and Compositions for Obtaining Mature Dendritic Cells
	F 6,300,110	Dec 23/98	Oct 9/01	435/194	Villeponteau B et al	Peptides Related to TPC2 and TPC3, Two Proteins that are Coexpressed with Telomerase Activity
	G 6,306,388	May 6/98	Oct 23/01	424/93.21	Nair SK et al	Methods for Treating Cancers and Pathogen Infections Using Antigen-Presenting Cells Loaded with RNA
	H 6,387,701	Apr 30/99	May 14/02	435/455	Nair SK et al	Method of Identifying Tumor Antigens that Elicit a T-Cell Response
	I 6,440,735	Sep 28/00	Aug 27/02	435/372.2	Gaeta FCA	Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
	J 6,444,650	Mar 31/98	Sep 3/02	514/44	Cech TR et al	Antisense Compositions for Detecting and Inhibiting Telomerase Reverse Transcriptase
	K 6,475,483	Nov 30/99	Nov 5/02	424/93.7	Steinman RM et al	Method for In Vitro Proliferation of Dendritic Cell Precursors and Their Use to Produce Immunogens for Treating Autoimmune Diseases
	L 6,475,789	Aug 14/97	Nov 5/02	435/366	Cech TR et al	Human Telomerase Catalytic Subunit: Diagnostic and Therapeutic Methods
	M 6,517,834	Nov 20/00	Feb 11/03	424/94.5	Weinrich SL et al	Purified Telomerase
	N 6,545,133	Nov 20/00	Apr 8/03	530/413	Weinrich SL et al	Methods for Purifying Telomerase
	O 6,610,839	Sep 29/99	Aug 26/03	536/24.1	Morin GB et al	Promoter for Telomerase Reverse Transcriptase

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**

Form 1449 (modified)	Docket: 086/002	U.S.S.N.: 10/602,441
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets if Necessary)	Title: Cancer Vaccines Containing Xenogeneic Epitopes of Telomerase Reverse Transcriptase Inventors: Anish Sen Majumdar, <i>et al.</i>	
	Filing Date: June 24, 2003	Group: 1642



FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Ref.	Document No.	Publication Date	Jurisdiction	Title	Translation
	P	EP 1093381 B1	Aug 20/03	EP	Antigenic Peptides Derived from Telomerase	N/A
	Q	WO 99/27113	Jun 3/99	PCT	Mouse Telomerase Reverse Transcriptase	N/A
	R	WO 99/63945	Dec 16/99	PCT	Vaccination Strategy to Prevent and Treat Cancers	N/A
	S	WO 00/46355	Aug 10/00	PCT	Telomerase Reverse Transcriptase Transcriptional Regulatory Sequences	N/A
	T	WO 00/61766	Oct 19/00	PCT	Telomerase-Specific Cancer Vaccine	N/A
	U	WO 00/73420	Dec 7/00	PCT	Creation of Human Tumorigenic Cells and Uses Therefor	N/A
	V	WO 01/60391	Aug 23/01	PCT	A Universal Vaccine and Method for Treating Cancer Employing Telomerase Reverse Transcriptase	N/A
	W	WO 01/74855	Oct 11/01	PCT	Compositions and Methods for Dendritic Cell-Based Immunotherapy	N/A
	X	WO 02/042445	May 30/02	PCT	Differentiated Cells Suitable for Human Therapy	N/A
	Y	WO 02/042468	May 30/02	PCT	Glycosyltransferase Vectors for Treating Cancer	N/A
	Z	WO 02/091999	Nov 21/02	PCT	Treatment for Wounds	N/A
	AA	WO 03/038047	May 8/03	PCT	Human Telomerase Reverse Transcriptase as a Class-II Restricted Tumor-Associated Antigen	

OTHER DOCUMENTS

Examiner Initial	Ref.	Author, Title, Source, Date
	AB	Alexander AN et al, Phase I/II Clinical Trial Utilizing a Tumor Cell Vaccine Encoding Xenogeneic Gp100 in Canine Patients with Metastatic Melanoma: Immunological and Clinical Outcomes, AACR Meeting Abstract No. 4158, San Francisco, CA (2002)
	AC	Ayyoub M et al, Lack of Tumor Recognition by hTERT Peptide 540-548-Specific CD8 <sup>+</sup> T Cells from Melanoma Patients Reveals Inefficient Antigen Processing, Eur J Immunol 31:2642 (2001)
	AD	Bellone M et al, <i>In Vitro</i> Priming of Cytotoxic T Lymphocytes Against Poorly Immunogenic Epitopes by Engineered Antigen-Presenting Cells, Eur J Immunol 24:2691 (1994)
	AE	Boczkowski D et al, Dendritic Cells Pulsed with RNA are Potent Antigen-Presenting Cells in Vitro and in Vivo, J Exp Med 184:465 (1996)
	AF	Bryan TM et al, Telomerase Reverse Transcriptase Genes Identified in <i>Tetrahymena Thermophila</i> and <i>Oxytricha Trifallax</i> , PNAS USA 95:8479 (1998)
	AG	Disis ML et al, Flt3 Ligand as a Vaccine Adjuvant in Association with HER-2/neu Peptide-based Vaccines in Patients with HER-2/neu-overexpressing Cancers, Blood 99 (8):2845 (2002)
	AH	Evans TG et al, The Use of Flt3 Ligand as an Adjuvant for Hepatitis B Vaccination of Healthy Adults, Vaccine 21:322 (2002)
	AI	Ferber IA et al, Telomerase Reverse Transcriptase as a Target for in Vivo Gene-Based Cancer Vaccination, Amn Assn Cancer Res Abstract 3007 (2002)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449 (modified)	Docket: 086/002	U.S.S.N.: 10/602,441
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Title: Cancer Vaccines Containing Xenogeneic Epitopes of Telomerase Reverse Transcriptase Inventors: Anish Sen Majumdar, <i>et al.</i>	
(Use Several Sheets if Necessary)	Filing Date: June 24, 2003	Group: 1642

MAR 09 2005

OTHER DOCUMENTS

Examiner Initial	Ref.	Author, Title, Source, Date
	AJ	Ferrone CR et al, 12: IgG Fusion Gene as a Molecular Adjuvant for Xenogeneic DNA Vaccines, Amn Society Gene Therapy Meeting Abstract No. 102, Boston, MA (2002)
	AK	Fong L et al, Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy, J Immunol 167:7150 (2001)
	AL	Frolkis M et al, Dendritic Cells Reconstituted with Human Telomerase Gene Induce Potent Cytotoxic T-Cell Response Against Different Types of Tumors, Cancer Gene Therapy 10:239 (2003)
	AM	Fu S et al, Use of Cosmid Adenoviral Vector Cloning System for the <i>In Vitro</i> Construction of Recombinant Adenoviral Vectors, Hum Gene Ther 8:1321 (1997)
	AN	Greener M, Telomerase: The Search for a Universal Cancer Vaccine, Mol Med Today 6:257 (2000)
	AO	Harley CB et al, Telomerase and Cancer, Important Adv Oncol p57 (1996)
	AP	Hawkins WG et al, Xenogeneic DNA Immunization in Melanoma Models for Minimal Residual Disease, J Surg Res 102:137 (2002)
	AQ	Heiser A et al, Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA, J Immunol 166:2953 (2001)
	AR	Hernández J et al, Identification of a Human Telomerase Reverse Transcriptase Peptide of Low Affinity for HLA A2.1 that Induces Cytotoxic T Lymphocytes and Mediates Lysis of Tumor Cells, PNAS 99(19):12275 (2002)
	AS	Kim NW et al, Specific Association of Human Telomerase Activity with Immortal Cells and Cancer, Science 266:2011 (1994)
	AT	Lev A et al, Isolation and Characterization of Human Recombinant Antibodies Endowed with the Antigen-Specific, Major Histocompatibility Complex-Restricted Specificity of T Cells Directed Toward the Widely Expressed Tumor T-Cell Epitopes of the Telomerase Catalytic Subunit, Cancer Res 62:3184 (2002)
	AU	Lichtsteiner SP et al, Telomerase. A Target for Anticancer Therapy, Ann NY Acad Sci 886:1 (1999)
	AV	Minev B et al, Cytotoxic T Cell Immunity Against Telomerase Reverse Transcriptase in Humans, PNAS 97(9):4796 (2000)
	AW	Miyake S et al, Efficient Generation of Recombinant Adenoviruses Using Adenovirus DNA-Terminal Protein Complex and a Cosmid Bearing the Full-Length Virus Genome, PNAS USA 93:1320 (1996)
	AX	Nair SK et al, Induction of Cytotoxic T Cell Responses and Tumor Immunity Against Unrelated Tumors Using Telomerase Reverse Transcriptase RNA Transfected Dendritic Cells, Nat Med 6(8):1011 (2000)
	AY	Nakamura TM et al, Telomerase Catalytic Subunit Homologs from Fission Yeast and Human, Science 277:955 (1997)
	AZ	Pomer S et al, Tumor Vaccination in Renal Cell Carcinoma with and without Interleukin-2 (IL-2) as Adjuvant. A Clinical Contribution to the Development of Effective Active Specific Immunization, Urolege A 34(3):215 (1995) Abstract
	BA	Simmons SJ et al, GM-CSF as a Systemic Adjuvant in a Phase II Prostate Cancer Vaccine Trial, Prostate 39:291 (1999)
	BB	Steitz J et al, Genetic Immunization of Mice with Human Tyrosinase-Related Protein2: Implications for the Immunotherapy of Melanoma, Int J Cancer 86:89 (2000)
	BC	Su Z et al, Immunological and Clinical Responses in Metastatic Renal Cancer Patients Vaccinated with Tumor RNA-Transfected Dendritic Cells, Cancer Res 63:2127 (2003)
	BD	Tanaka M et al, Induction of a Systemic Immune Response by a Polyvalent Melanoma-Associated Antigen DNA Vaccine for Prevention and Treatment of Malignant Melanoma, Molecular Ther 5(3):291 (2002)
	BE	Wolchok JD et al, Of Mice and Men (and Dogs): Xenogeneic DNA Vaccines for Melanoma, Amn Society Gene Therapy Meeting Abstract No. 218, Boston, MA (2002)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.